Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 192

1.

Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.

Nishida S, Matsumura T, Senokuchi T, Murakami-Nishida S, Ishii N, Morita Y, Yagi Y, Motoshima H, Kondo T, Araki E.

Biochem Biophys Res Commun. 2020 Jan 18. pii: S0006-291X(20)30072-3. doi: 10.1016/j.bbrc.2020.01.027. [Epub ahead of print]

PMID:
31964532
2.

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.

Araki E, Watada H, Uchigata Y, Tomonaga O, Fujii H, Ohashi H, Okabe T, Asano M, Thoren F, Kim H, Yajima T, Langkilde AM.

Diabetes Obes Metab. 2019 Nov 19. doi: 10.1111/dom.13922. [Epub ahead of print]

PMID:
31742898
3.

Clinical Features of Patients with Acute Aortic Dissection After an Earthquake ~Experience from The Kumamoto Earthquake 2016~.

Komorita T, Fujisue K, Sueta D, Sakamoto K, Yamamoto E, Hashimoto Y, Sakamoto T, Tsunoda R, Uesugi H, Suzuki R, Naito H, Hanzawa K, Araki E, Nakayama H, Kasaoka S, Hokimoto S, Fukui T, Tsujita K.

Am J Hypertens. 2019 Nov 18. pii: hpz183. doi: 10.1093/ajh/hpz183. [Epub ahead of print]

PMID:
31738384
4.

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.

Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S.

Int J Mol Sci. 2019 Nov 6;20(22). pii: E5537. doi: 10.3390/ijms20225537.

5.

Differential predictive factors for cardiovascular events in patients with or without cancer history.

Sueta D, Tabata N, Ikeda S, Saito Y, Ozaki K, Sakata K, Matsumura T, Yamamoto-Ibusuki M, Murakami Y, Jodai T, Fukushima S, Yoshida N, Kamba T, Araki E, Iwase H, Fujii K, Ihn H, Kobayashi Y, Minamino T, Yamagishi M, Maemura K, Baba H, Matsui K, Tsujita K.

Medicine (Baltimore). 2019 Nov;98(44):e17602. doi: 10.1097/MD.0000000000017602.

6.

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators.

Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17.

PMID:
31530667
7.

Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.

Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y.

Adv Ther. 2019 Oct;36(10):2697-2711. doi: 10.1007/s12325-019-01065-7. Epub 2019 Sep 3.

8.
9.

Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.

Shimoda S, Sakamoto W, Hokamura A, Matsuo Y, Sekigami T, Ichimori S, Iwashita S, Ishii N, Otsu K, Yoshimura R, Nishiyama T, Sakaguchi M, Nishida K, Araki E.

Endocr J. 2019 Aug 29;66(8):745-752. doi: 10.1507/endocrj.EJ19-0179. Epub 2019 Jul 12.

10.

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.

Langer J, Wolden ML, Shimoda S, Sato M, Araki E.

Diabetes Ther. 2019 Aug;10(4):1347-1356. doi: 10.1007/s13300-019-0635-1. Epub 2019 Jun 5.

11.

Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ.

Murakami-Nishida S, Matsumura T, Senokuchi T, Ishii N, Kinoshita H, Yamada S, Morita Y, Nishida S, Motoshima H, Kondo T, Komohara Y, Araki E.

Atherosclerosis. 2019 Jul;286:30-39. doi: 10.1016/j.atherosclerosis.2019.04.229. Epub 2019 May 3.

PMID:
31096071
12.

Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets.

Goto R, Kondo T, Ono K, Kitano S, Miyakawa N, Watanabe T, Sakaguchi M, Sato M, Igata M, Kawashima J, Motoshima H, Matsumura T, Shimoda S, Araki E.

J Clin Med. 2019 May 14;8(5). pii: E674. doi: 10.3390/jcm8050674.

13.

FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism.

Sakaguchi M, Cai W, Wang CH, Cederquist CT, Damasio M, Homan EP, Batista T, Ramirez AK, Gupta MK, Steger M, Wewer Albrechtsen NJ, Singh SK, Araki E, Mann M, Enerbäck S, Kahn CR.

Nat Commun. 2019 Apr 5;10(1):1582. doi: 10.1038/s41467-019-09418-0.

14.

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.

Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S.

Diabetes Obes Metab. 2019 Jul;21(7):1737-1744. doi: 10.1111/dom.13686. Epub 2019 Apr 1.

15.

Correction to: Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

Diabetol Int. 2018 Dec 4;10(1):83. doi: 10.1007/s13340-018-0385-8. eCollection 2019 Jan.

16.

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.

Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S, Of The K-Study Group OB.

Int J Mol Sci. 2019 Feb 6;20(3). pii: E706. doi: 10.3390/ijms20030706.

17.

Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus.

Kondo T, Nakamura M, Kawashima J, Matsumura T, Ohba T, Yamaguchi M, Katabuchi H, Araki E.

Endocr J. 2019 Mar 28;66(3):253-258. doi: 10.1507/endocrj.EJ18-0496. Epub 2019 Jan 29.

18.

Japanese Clinical Practice Guideline for Diabetes 2016.

Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E.

Diabetol Int. 2018 Mar 27;9(1):1-45. doi: 10.1007/s13340-018-0345-3. eCollection 2018 Feb. Review. No abstract available. Erratum in: Diabetol Int. 2018 Dec 4;10(1):83.

19.

Impact of hepatic HSP72 on insulin signaling.

Kitano S, Kondo T, Matsuyama R, Ono K, Goto R, Takaki Y, Hanatani S, Sakaguchi M, Igata M, Kawashima J, Motoshima H, Matsumura T, Kai H, Araki E.

Am J Physiol Endocrinol Metab. 2019 Feb 1;316(2):E305-E318. doi: 10.1152/ajpendo.00215.2018. Epub 2018 Dec 11.

PMID:
30532989
20.

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.

Watada H, Shiramoto M, Ueda S, Tang W, Asano M, Thorén F, Kim H, Yajima T, Boulton DW, Araki E.

Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13593. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center